• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄相关性黄斑变性继发脉络膜新生血管膜患者玻璃体内注射贝伐单抗后出现可逆性后部脑病综合征。

Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.

机构信息

Department of Ophthalmology, Istanbul Bilim University, Istanbul, Turkey.

出版信息

J Ocul Pharmacol Ther. 2010 Jun;26(3):301-3. doi: 10.1089/jop.2009.0148.

DOI:10.1089/jop.2009.0148
PMID:20565319
Abstract

The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.

摘要

后部可逆性脑病综合征(PRES)是一种包括头痛、癫痫、视觉障碍在内的脑部疾病,与多种血压急剧升高的疾病相关。贝伐单抗全身给药可导致动脉高血压。有少数贝伐单抗全身注射引起 PRES 的病例报道。本文首次报道了 1 例玻璃体腔注射贝伐单抗后发生 PRES 的患者。

相似文献

1
Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.年龄相关性黄斑变性继发脉络膜新生血管膜患者玻璃体内注射贝伐单抗后出现可逆性后部脑病综合征。
J Ocul Pharmacol Ther. 2010 Jun;26(3):301-3. doi: 10.1089/jop.2009.0148.
2
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗(阿瓦斯汀)治疗新生血管性年龄相关性黄斑变性的短期安全性和疗效
Retina. 2006 May-Jun;26(5):495-511. doi: 10.1097/01.iae.0000225766.75009.3a.
3
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性中心凹下脉络膜新生血管:泛美视网膜协作研究组12个月随访结果
Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.
4
Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性先前治疗过的脉络膜新生血管。
Retina. 2007 Apr-May;27(4):432-8. doi: 10.1097/IAE.0b013e318042b53f.
5
Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab.玻璃体内注射贝伐单抗后,未治疗的对侧眼亚临床年龄相关性黄斑变性快速进展。
Acta Ophthalmol. 2009 Sep;87(6):685-7. doi: 10.1111/j.1755-3768.2008.01281.x. Epub 2009 Aug 13.
6
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.玻璃体内注射贝伐单抗(阿瓦斯汀)治疗新生血管性年龄相关性黄斑变性:一项短期研究。
Am J Ophthalmol. 2007 Mar;143(3):510-2. doi: 10.1016/j.ajo.2006.10.004. Epub 2006 Nov 13.
7
Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性:连续三个月每月注射的疗效
Am J Ophthalmol. 2008 Jul;146(1):91-5. doi: 10.1016/j.ajo.2008.03.014. Epub 2008 May 2.
8
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性:一项为期一年的前瞻性研究。
Am J Ophthalmol. 2008 Feb;145(2):249-256. doi: 10.1016/j.ajo.2007.09.031. Epub 2007 Dec 11.
9
Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性后发生的视网膜色素上皮撕裂
Acta Ophthalmol Scand. 2006 Dec;84(6):833-4. doi: 10.1111/j.1600-0420.2006.00765.x.
10
Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.基于光学相干断层扫描的治疗方案对新生血管性年龄相关性黄斑变性应用玻璃体内注射贝伐单抗(阿瓦斯汀)的疗效:6 个月和 12 个月的结果。
Acta Ophthalmol. 2010 Aug;88(5):594-600. doi: 10.1111/j.1755-3768.2008.01485.x. Epub 2009 May 22.

引用本文的文献

1
Effects of intravitreal injection of bevacizumab on nitric oxide levels.玻璃体内注射贝伐单抗对一氧化氮水平的影响。
Eye (Lond). 2015 Mar;29(3):436-42. doi: 10.1038/eye.2014.297. Epub 2014 Dec 19.
2
Anti-VEGF Cancer Therapy in Nephrology Practice.肾脏病学实践中的抗血管内皮生长因子癌症治疗
Int J Nephrol. 2014;2014:143426. doi: 10.1155/2014/143426. Epub 2014 Aug 24.
3
The VEGF pathway in cancer and disease: responses, resistance, and the path forward.血管内皮生长因子(VEGF)通路与癌症和疾病:反应、抵抗和未来方向。
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a006593. doi: 10.1101/cshperspect.a006593.
4
[Acute bilateral loss of vision in posterior reversible encephalopathy syndrome].[后部可逆性脑病综合征所致急性双侧视力丧失]
Ophthalmologe. 2013 Mar;110(3):247-50. doi: 10.1007/s00347-012-2614-z.
5
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.抗 VEGF 药物引起的后部可逆性脑病综合征。
Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17.